The purpose of the study is to continue to follow subjects who were enrolled in the CTOT-20 CLAD Phenotypes study. Subjects will provide clinical data and complete quality of life questionnaires that will be used to determine the clinical factors associated with the development of Chronic Lung Allograft Dysfunction (CLAD) after lung transplant.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Time from lung transplant to Chronic Lung Allograft Dysfunction (CLAD) (including RCLAD or BOS) as measured by serial pulmonary function tests
Timeframe: Baseline, up to 24 months
Number of participants that develop CLAD as measured by change in pulmonary function and Physician Adjudication
Timeframe: Up to 24 months
Number of participants that have Th1, Th2, Th17 immune profiles as measured in the lung fluid
Timeframe: Up to 24 months
Number of participants that have Th1, Th2, and Th17 immune profiles as measured in the blood
Timeframe: Up to 24 months